Author

No. of patients

Stage IVA

(%)

Induction chemotherapy regimen

% of patients with GCSF

% for patients completing 3 cycles TPF

% of patients receiving planned dose TPF

Concurrent cisplatin compliance

G3/4 toxicities

Survival outcomes

Sun et al.

[11]

480

45.4

Docetaxel 60 mg/m² D1

Cisplatin 60 mg/m² D1

5FU 600 mg/m² D1-5

Q3 weeks

0

88

78

79% received ≥ 200 mg/m²

Neutropenia – 35%

Neutropenic fever – 2.5 %

Mucositis- 6.5%

Diarrhea – 7%

3-year OS 85.6%

3-year PFS 77.4%

Frikha et al.

[10]

83

NR

Docetaxel 75 mg/m² D1

Cisplatin 75 mg/m² D1

5FU 750 mg/m² D1-5

Q3 weeks

15

95

75

86 % received  ≥200 mg/m²

Neutropenia -27.5%

Neutropenic fever – 7.5

Mucositis- 12.5%

Diarrhea -

3-year OS 86.3%

3-year PFS 73.9%

Present study

28

100

Docetaxel 75 mg/m² D1

Cisplatin 75 mg/m² D1

5FU 750 mg/m² D1-5

Q3 weeks

100

93

71

Mean dose of cisplatin received : 221 mg/m²

Neutropenia -11%

Neutropenic fever – 3.6%

Mucositis- 0%

Diarrhea – 8%

*3-year OS 100%

^§3-year PFS 92.2%